TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11763512
Drug: Trisekvens plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trisekvens plus betaksolol (10‐20 mg/day)
Study: 30477210
Drug: Intensive oral
Normalized name: Uricalm Intensive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive oral health instruction at baseline and self-assessment every three months
Study: 30477210
Drug: Intensive oral
Normalized name: Uricalm Intensive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive oral health instruction
Study: 27345158
Drug: E2/NETA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (1 mg estradiol and 0.5 mg norethisterone acetate)
Study: 9251452
Drug: Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium Nitroprusside (SNP) added peritoneal dialysis (PD) with 36 cycles of intermittent PD, exchange volume of 1 litre, duration of 1 hour per cycle, SNP dose of 4 mg/litre in alternate clearance periods.
Study: 6698337
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment (2 g per day for one week)
Study: 6698337
Drug: Aspirin vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin vs. Lysine acetylsalicylate
Study: 17846548
Drug: Sinus augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinus augmentation with 100% autologous bone
Study: 17846548
Drug: Sinus augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinus augmentation with 100% Bio‐Oss
Study: 11779741
Drug: Oral jaw-positioning
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral jaw-positioning appliance (6-month trial)
Study: 9678813
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. and tinidazole 500 mg b.d. (group RBCCT)
Study: 9678813
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. plus amoxycillin 1 g b.d. (group RBCCA)
Study: 7862890
Drug: Nicotine injections
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine injections (0.6 mg, subcutaneous, two injections 40 min apart)
Study: 19925973
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic plus buprenorphine 0.3 mg
Study: 17000354
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine treatment
Study: 17000354
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between morphine-treated group and controls
Study: 12680861
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT) with standardized Dermatophagoides pteronyssinus (D.pt.) and D. farinae (D.f.) 50/50 extract
Study: 12680861
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT)
Study: 1559524
Drug: Low-density (LD)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-density (LD) diet (50 kcal/100 g)
Study: 1559524
Drug: High-density (HD)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density (HD) diet (100 kcal/100 g)
Study: 28003127
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered 60-75 minutes before learning or recall
Study: 28003127
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered immediately after learning or recall
Study: 23702185
Drug: Neonatal Vitamin
Normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal Vitamin A Supplementation (VAS) with BCG vaccine
Study: 23702185
Drug: Neonatal Vitamin
Normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal Vitamin A Supplementation (VAS) without BCG vaccine
Study: 23702185
Drug: Neonatal Vitamin
Normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal Vitamin A Supplementation (VAS) among children who had not received DTP vaccine
Study: 23702185
Drug: Neonatal Vitamin
Normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal Vitamin A Supplementation (VAS) among children who had received DTP vaccine
Study: 12957348
Drug: Integrated Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Family and Cognitive‐Behavioral Therapy (IFCBT)
Study: 12957348
Drug: Drugs Harm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs Harm Psychoeducation curriculum (DHPE)
Study: 11138645
Drug: High-potency, high-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency, high-frequency fluoride brush-on gel
Study: 11138645
Drug: High-potency, high-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency, high-frequency fluoride gel dentifrice
Study: 10778622
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg per day)
Study: 30127143
Drug: After two
Approvals — FDA: no, EMA: no, PMDA: no
Description: After two injections
Study: 27515871
Drug: Spiritist 'passe'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiritist 'passe' energy therapy (8 weekly sessions)
Study: 27515871
Drug: Sham Spiritist
Normalized name: TURPENTINE SPIRITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Spiritist 'passe' sessions (8 weekly sessions)
Study: 27515871
Drug: Spiritist 'passe'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiritist 'passe' energy therapy
Study: 18317456
Drug: Glutamine-enriched parenteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched parenteral nutrition (GlPN, n=27)
Study: 18317456
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (PN, n=26)
Study: 16503885
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate (0.05%) cream twice daily
Study: 16503885
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (0.005%) twice daily
Study: 16503885
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of betamethasone dipropionate (0.05%) in the morning and calcipotriol (0.005%) in the evening
Study: 11153584
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules containing 84 mg eicosapentaenoic acid (EPA) and 36 mg docosahexaenoic acid (DHA)
Study: 11153584
Drug: Control capsules
Normalized name: Azo Men Bladder Control Capsules(obs)
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control capsules containing 300 mg olive oil
Study: 2945833
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of KOB and buddy programs
Study: 29135277
Drug: Neuromuscular Manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular Manual Therapy (NMT)
Study: 29135277
Drug: Standard Pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Pharmacological Treatment (PT)
Study: 24647231
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000mg plus prednisone 5mg twice daily
Study: 18678158
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Fenbid slow-released capsules
Study: 20499152
Drug: Risky sexual
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risky sexual behaviors within a couple and with concurrent sexual partners
Study: 9876949
Drug: 720 ELISA
Normalized name: hepatitis A virus vaccine 720 ELISA unit/0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 ELISA Units (EL.U) inactivated hepatitis A vaccine, 0, 6‐month schedule
Study: 9876949
Drug: 360 ELISA
Normalized name: hepatitis A virus vaccine 360 ELISA unit/0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 ELISA Units (EL.U) inactivated hepatitis A vaccine, 0, 1, 6‐month schedule
Study: 7978126
Drug: Endotoxin antibody
Normalized name: endotoxin antibody Ha-1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin antibody (hypothetical intervention)
Study: 29927386
Drug: AL-794 (50-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-794 (50-2000 mg single ascending doses)
Study: 29927386
Drug: AL-794 (50-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-794 (50-600 mg multiple ascending doses, twice-daily)
Study: 29927386
Drug: AL-794 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-794 (450 mg following a high-fat meal)
Study: 25301459
Drug: IN.PACT Amphirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN.PACT Amphirion drug‐eluting balloons (IA‐DEB)
Study: 22730693
Drug: Xuebejing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebejing injection combined with conventional therapy
Study: 20299778
Drug: Intravesically applied
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesically applied amikacin (1 g in adults and 30 mg/kg in pediatric patients)
Study: 17195701
Drug: Single-dose ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ceftriaxone
Study: 17195701
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (cefprozil, amoxicillin, azithromycin)
Study: 2200997
Drug: Cefotiam 1
Normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotiam 1 g preoperative dose
Study: 2200997
Drug: Cefazoline 3
Normalized name: cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazoline 3 g perioperatively
Study: 25995313
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg)
Study: 30322973
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of fentanyl: 1 mcg/kg loading dose followed by 1 mcg/kg/hour infusion
Study: 30322973
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus (IB) doses of fentanyl: 1 mcg/kg/dose every 4 hours
Study: 25648989
Drug: l-NMMA infusion
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-NMMA infusion
Study: 25648989
Drug: TEA infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEA infusion
Study: 25648989
Drug: l-NMMA +
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-NMMA + TEA infusion
Study: 24953015
Drug: Extrafine beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI, 2 inhalations BID
Study: 24953015
Drug: FOR 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOR 12 μg pMDI, 1 inhalation BID
Study: 22928824
Drug: Gua Sha
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Gua HC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gua Sha therapy (single treatment)
Study: 793848
Drug: Metoprolol 75
Normalized name: metoprolol 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 75 mg daily (increased to 450 mg max)
Study: 793848
Drug: Alpha-methyldopa 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-methyldopa 375 mg daily (increased to 2250 mg max)
Study: 21838410
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once daily (after starting dose of 30 mg QD for 1 week)
Study: 19647467
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin, administered twice a day for 36 months
Study: 9806254
Drug: 5 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg triptorelin acetate s.c. daily
Study: 9806254
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg triptorelin acetate s.c. daily
Study: 9806254
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg triptorelin acetate s.c. daily
Study: 9806254
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg triptorelin acetate s.c. daily
Study: 871198
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml 4% lignocaine spray
Study: 30267738
Drug: RNase1 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RNase1 treatment (pre-treated with RNase1 24 hours before A. hydrophila injection)
Study: 25500425
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 10 mg, 25 mg, or 50 mg once daily for 3 months
Study: 21975193
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) plus treatment as usual (TAU)
Study: 19291747
Drug: 1540 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1540 nm fractional laser treatments (three monthly treatments)
Study: 16904063
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy package for generalized anxiety disorder (GAD)
Study: 11239729
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment condition
Study: 15151713
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of human menopausal gonadotrophin (HMG) by 75 IU on the day of antagonist administration (Group B)
Study: 15151713
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of human menopausal gonadotrophin (HMG) (Group A)
Study: 10654498
Drug: Heparin‐coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐coated circuit with silicone‐coated oxygenator (Group A)
Study: 10654498
Drug: Whole heparin‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole heparin‐coated circuit (Group B)
Study: 8161673
Drug: PEG‐ELS 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐ELS 4 L plus simethicone 120 mg
Study: 8161673
Drug: PEG‐ELS 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐ELS 4 L plus placebo
Study: 2868339
Drug: UKALL VIII
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UKALL VIII treatment regimen including continuous therapy during induction, long course of intramuscular asparaginase over 3 weeks, full-dose mercaptopurine and co-trimoxazole during CNS prophylaxis, sustained maximum tolerated doses of mercaptopurine and methotrexate maintenance.
Study: 2868339
Drug: UKALL VII
Normalized name: factor VII
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UKALL VII treatment regimen for good-prognosis patients.
Study: 2582828
Drug: MDI-spacer (0.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI-spacer (0.36 mg of albuterol)
Study: 2582828
Drug: Nebulizer (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer (2.5 mg of albuterol)
Study: 23017611
Drug: Avoiding life-sustaining
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoiding life-sustaining therapies
Study: 14964743
Drug: Topical fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluorouracil cream (0.5% 5-fluorouracil in a microsphere vehicle)
Study: 2687008
Drug: Salbutamol controlled-release
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol controlled-release (SCR) 4 mg
Study: 2687008
Drug: Salbutamol controlled-release
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol controlled-release (SCR) 8 mg
Study: 1103400
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen of streptomycin, isoniazid, and pyrazinamide
Study: 1103400
Drug: 3 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times weekly regimen of streptomycin, isoniazid, and pyrazinamide
Study: 1103400
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly regimen of streptomycin, isoniazid, and pyrazinamide
Study: 1103400
Drug: Overall relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall relapse rates after 6 months' chemotherapy
Study: 1103400
Drug: Overall relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall relapse rates after 9 months' chemotherapy
Study: 28643323
Drug: Early intensified
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensified protocol of six cycles of CHOP-14 with dose-dense rituximab and high-dose methotrexate
Study: 28643323
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles R-CHOP-21 followed by first-line high-dose chemotherapy with autologous stem-cell support (HDCT-ASCT)
Study: 20689320
Drug: Vitamin K₂
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K₂ (menatetrenone) 45 mg/day for 1 year
Study: 17084786
Drug: Treatment condition,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment condition, session sequence, and session date
Study: 15643481
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (SH) injection (2 ml, Hyalgan, 20 mg/2 ml; once a week for 5 weeks)
Study: 15643481
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution (once a week for 3 weeks)
Study: 2971582
Drug: 5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl peroxide/2% miconazole cream (BPO-MCZ)
Study: 2971582
Drug: 5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl peroxide gel (BPO)
Study: 31473172
Drug: IAI 2
Normalized name: Intravitreal aflibercept injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAI 2 mg every 8 weeks (2q8)
Study: 26832658
Drug: IAI 2
Normalized name: Intravitreal aflibercept injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAI 2 mg every 4 weeks (2q4)
Study: 23208967
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dexketoprofen 30 minutes prior to the operation (group 50/0)
Study: 23208967
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dexketoprofen 30 minutes after the operation (group 0/50)
Study: 23208967
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dexketoprofen both 30 minutes prior and 30 minutes after the operation (group 25/25)
Study: 19997572
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) therapy for four weeks
Study: 9694028
Drug: Methysergide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methysergide (2 mg)
Study: 3071459
Drug: Ketanserin 10
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 10 to 30 mg twice daily
Study: 3071459
Drug: Propranolol 20
Normalized name: propranolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 20 to 40 mg 3 times daily
Study: 31050660
Drug: GR mirror
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GR mirror therapy
Study: 31050660
Drug: Conventional mirror
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional mirror therapy
Study: 31006282
Drug: Hourly titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly titrated oral misoprostol
Study: 23999422
Drug: Dinoprostone 10
Normalized name: dinoprostone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone 10 mg vaginal insert
Study: 22094327
Drug: EBRT dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT dose of 70.2 Gy
Study: 22094327
Drug: EBRT dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT dose of 79.2 Gy
Study: 15922815
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg/Ibuprofen 400 mg
Study: 15922815
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg/Acetaminophen 325 mg
Study: 15922815
Drug: Hydrocodone 7.5
Normalized name: HYDROCODONE 7.5/IBUPROFEN 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone 7.5 mg/Acetaminophen 500 mg
Study: 12533165
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (Dysport, 100 U dissolved in 0.9% sodium chloride solution)
Study: 8646728
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/m2 i.v.), Epirubicin (60 mg/m2 i.v.), Vindesine (3 mg/m2 i.v.)
Study: 8646728
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/m2 i.v.), Epirubicin (60 mg/m2 i.v.), Vindesine (3 mg/m2 i.v.) + Lonidamine (75 mg orally three times on Day 1 to 150 mg orally three times on Day 7+)
Study: 29765102
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral CBD
Study: 17882808
Drug: Mildronate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildronate (1 g/day) in addition to basic therapy